Wockhardt Hospital

Keep eye on Wockhardt Hospital.
If one manages to look ahead of the IPO debacle and the losses on derivatives incurred now, the company does seem to be moving ahead. Its acquisition of Negma Laboratories in France and Morton Grove Pharmaceuticals in the US has shown a remarkable performance. And this acquisition helped the company improve its operating profits.

The company said that Europe continues to be its single largest market accounting for 54% of its consolidated sales. The company’s US business grew by 141%. The company markets 58 products in the US market.

At this juncture, it will be very difficult for the punters to look ahead. The market fancy for the stock is at its ebb. Quoted at Rs.301, it has recouped from the low of Rs.245 it touched on 24th March. Hold on, maybe the bad times are behind and the company is back on track.

source s.p. tulsian.